NEW YORK (GenomeWeb) – Quidel reported after the close of the market on Monday that its first quarter revenues rose 46 percent year over year, thanks largely to higher sales of immunoassay, molecular, and specialty products.

For the three months ended March 31, revenues rose to $73.7 million from $50.3 million in Q1 2016, and beat the average analysts' estimate of $62.0 million.

The firm said that influenza revenues rose 112 percent to $40.8 million year over year, thanks to a severe and longer-than-usual respiratory disease season.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.